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Available online 23 September 2016Animal models are critical to understand disease and to develop countermeasures for the ongoing epidemics of
Zika virus (ZIKV). Herewe report a non-humanprimatemodel using a 2016 contemporary clinical isolate of ZIKV.
Upon subcutaneous inoculation, rhesus macaques developed fever and viremia, with robust excretion of ZIKV
RNA in urine, saliva, and lacrimal ﬂuid. Necropsy of two infected animals revealed that systematic infections in-
volving central nervous system and visceral organs were established at the acute phrase. ZIKV initially targeted
the intestinal tracts, spleen, and parotid glands, and retained in spleen and lymph nodes till 10 days post infec-
tion. ZIKV-speciﬁc immune responses were readily induced in all inoculated animals. The non-human primate
model described here provides a valuable platform to study ZIKV pathogenesis and to evaluate vaccine and
therapeutics.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Lacrimal ﬂuid1. Introduction
Zika virus (ZIKV) used to be an obscure mosquito-borne ﬂavivirus
from Flavivirus genus within Flaviviridae family. Other ﬂaviviruses of
global importance include dengue virus (DENV), West Nile virus
(WNV), yellow fever virus (YFV), Japanese encephalitis virus (JEV),
and tick-borne encephalitis virus (TBEV). ZIKV is phylogenetically divid-
ed into two lineages: the African and Asian lineages (Haddow et al.,
2012). Since 2007, the Asian lineage of ZIKV has caused epidemics in
Polynesia, the South Paciﬁc, and most recently the Americas, leading
to global concerns about its association with microcephaly and severe
neurologic disorders (Gulland, 2016). The causal linkage between
ZIKV infection and microcephaly, initially indicated by clinical studies,
has recently been recapitulated in mouse models. ZIKV can infect306th Hospital of PLA, Beijing,
. This is an open access article undermouse fetus, resulting in intrauterine growth restriction, placental dam-
age, microcephaly, and fetal demise (Cugola et al., 2016; Li et al., 2016;
Miner et al., 2016; Wu et al., 2016).
Despite the above progress, the pathogenesis and transmission of
ZIKV remain largely unknown. Recent data suggested human dermal ﬁ-
broblasts, epidermal keratinocytes, placental macrophages and neural
progenitor cells were permissive to ZIKV infection (Hamel et al., 2015;
Li et al., 2016; Quicke et al., 2016; Tang et al., 2016). Results from
mouse model suggest that ZIKV replicates efﬁciently in embryonic
mouse brain by directly targeting neural progenitor cells and causing
apoptosis (Cugola et al., 2016; Li et al., 2016). In patients, infectious
ZIKV particles have been detected in blood, urine (Zhang et al., 2016),
saliva (Barzon et al., 2016), and breastmilk (Dupont-Rouzeyrol et al.,
2016). There is increasing evidence of sexual transmission of ZIKV
(D'Ortenzio et al., 2016; Moreira et al., 2016), and ZIKV RNA and infec-
tious particles have been detected in semen in ZIKV-infected patients
(Atkinson et al., 2016; Mansuy et al., 2016) or testis in infected mice
(Lazear et al., 2016; Miner et al., 2016). However, due to the highly cor-
related nature of sexual behaviors, sexual and close contact transmis-
sion by saliva or other body ﬂuids can be difﬁcult to distinguish,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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diated transmission remains to be determined. The knowledge of in
vivo replication, excretion kinetics, and target tissues/organs of ZIKV is
urgently needed for understanding the disease and pathogenesis.
No vaccines and antiviral drugs are currently available to prevent
and treat ZIKV infection. Animal models are essential for the develop-
ment of such countermeasures. Young A129 mice (lacking interferon
α/β receptor) and AG129 (lacking interferon α/β and γ receptors)
were recently reported to succumb to ZIKV infection and to develop
neurological signs (Aliota et al., 2016; Lazear et al., 2016; Malone et
al., 2016). Since these mousemodels are deﬁcient in innate immune re-
sponse, an immune competent animal model is needed. Non-human
primates have been well documented as a more relevant animal
model for ﬂavivirus infections (Sariol and White, 2014; Zompi and
Harris, 2012), and have beenwidely used for DENV andWNVpathogen-
esis studies and vaccine efﬁcacy tests (Sariol and White, 2014). ZIKV
was ﬁrst isolated from a febrile rhesus macaques (Dick et al., 1952).
Multiple monkey species in forests were found to be seropositive for
ZIKV (McCrae and Kirya, 1982), suggesting that non-human primates
can be infected and support viral replication.
Initial experiments performed in 1950s showed that rhesus mon-
keys inoculated subcutaneously (s.c.) or intracerebrally (i.c.) with the
African ZIKV strainMR766 developed no signs of pyrexia, but generated
antibodies within 2 to 3 weeks after infection (Dick, 1952). However,
bioinformatics analysis suggests that the ongoing epidemic strains in
the Americas have accumulated some amino acid changes that might
contribute to the explosive epidemics (Faria et al., 2016; Wang et al.,
2016). Here, we have established a non-human primate model using a
contemporary ZIKV strain GZ01/2016 (GenBank accession no:
KU820898) that was isolated from a patient returned from Venezuela
to China in 2016 (Zhang et al., 2016). ZIKV infection upon subcutaneous
in rhesusmacaques resulted in fever, viremia, and robust viral shedding
in multiple body ﬂuids including saliva, urine, and lacrimal ﬂuids. The
major target organs of ZIKV and speciﬁc immune response in non-
human primateswere also characterized in detail. Our study establishes
the non-human primate model of ZIKV infection with contemporary
clinical isolate that will be valuable for evaluating candidate vaccines
and therapeutics as well as understanding ZIKV pathogenesis, dissemi-
nation and transmission.
2. Materials & Methods
2.1. Ethics Statement
All animal experiments were performed in strict accordance with
the guidelines of the Chinese Regulations of Laboratory Animals (Minis-
try of Science and Technology of People's Republic of China) and Labo-
ratory Animal-Requirements of Environment and Housing Facilities
(GB 14925-2010, National Laboratory Animal Standardization Technical
Committee). All procedures were performed under sodium pentobarbi-
tal anesthesia by trained technicians and all efforts were made to ame-
liorate the welfare and tominimize animal suffering in accordancewith
the “Weather all report for the use of non-human primates” recommen-
dations. The experimental protocols were approved by the Animal Ex-
periment Committee of Laboratory Animal Center, AMMS, China
(IACUC-13-2016-001).
2.2. Viruses and Cells
ZIKV strain GZ01/2016 (GenBank number KU820898) was isolated
from a Chinese male patient returned from Venezuela (Zhang et al.,
2016). ZIKV stocks were propagated in Aedes albopictus C6/36 cells
and titrated by plaque forming assay on BHK-21 cells (Dai et al., 2016;
Deng et al., 2016). Studies with infectious ZIKV were conducted under
biosafety level 2 (BSL-2) facilities at Beijing Institute of Microbiology
and Epidemiology.2.3. Study Design
This studywas designed to establish the infectivity and viral dynam-
ics of currently circulating Asian lineage ZIKV. Five 5-year-old rhesus
monkeys (weighing 5.0 to 6.0 kg) in good healthwere prescreened neg-
ative for IgG antibodies against ﬂaviviruses (including ZIKV, DENV, JEV
and YFV) by enzyme-linked immunosorbent assay (ELISA). All the ani-
mals were housed individually in a single cage in pathogen-free facility,
and acclimatized for a week. Rhesus monkeys were s.c. inoculated with
105 PFU (equivalent to 108.5 RNA copies) of ZIKV. After the inoculation,
clinical signs were recorded during 34-day observation period. Blood
and major body ﬂuids were collected for determination of viral load.
Two rhesus monkeys were euthanasia to perform hematoxylin and
eosin (HE) and immunohistochemistry as well as virological analysis
for evaluation of viral tropism.
2.4. Body Fluids Collection
Urine was collected from a container under the animal's cage, and
was stored at−80 °C until analysis. Saliva was obtained by running a
sterile swab under the animal's tongue. Lacrimal ﬂuid was collected by
gently running a sterile swab on the animal's eye. Cerebrospinal ﬂuid
(CSF) was collected by lumbar puncture at the time of necropsy.
Swabs were placed immediately into 1.0 ml of viral transport medium
(tissue culturemedium 199 supplemented with 0.5% FBS and 1% antibi-
otic/antimycotic) for 60 min. Samples were vortexed vigorously, then
centrifuged for 10min at 3000 rpmbefore removing the swabs. Samples
were stored at−80 °C until processing.
2.5. Necropsy
Two s.c. inoculated rhesus monkeys were euthanized at days 5 and
10 p.i. by infusion of pentobarbital, and necropsy was performed. Sam-
ples were collected from the following tissues: cerebrum, cerebellum,
brain stem, spinal cord, lacrimal gland, parotid gland, lung, liver, spleen,
stomach, left and right kidneys, small intestine, large intestine, cecum,
prostate, epididymis, pancreas, adrenal gland, inguinal lymph nodes,
heart, urinary bladder, testis and muscle. All samples were snap frozen
for ZIKV-RNA detection and PFU assay. In brief, 1 ml of DMEM with 2%
FBS and penicillin/streptomycin was placed in an Eppendorf tube. The
organ was weighed and placed in the tube. Tissues were homogenized
for 30 s. The homogenate was clariﬁed by centrifugation for 5 min at
5000 rpm. The supernatants of tissueswere collected for RNA extraction
and virus isolation.
2.6. Histology and Immunohistochemistry
Collected tissues from inoculated monkeys were ﬁxed with perfu-
sion ﬁxative (formaldehyde) for 48 h, and processed according to stan-
dard histological assays. All sections from each tissue were stained with
hematoxylin and eosin (H&E). For immunohistochemistry, sections
were deparafﬁnized with xylene, rehydrated through successive bathes
of ethanol/water (from 100% ethanol successively to 50% ethanol till
pure water) and incubated in 3% H2O2 at room temperature. The sec-
tions were then put in 10 mM sodium citrate buffer for 1 h at 96 °C for
antigen retrieval and blocked with BSA at saturation for 20 min. Mono-
clonal mouse anti-ZIKV E protein antibody 2A10G6 (Dai et al., 2016)
was applied to the section overnight at 4 °C. Horse radish peroxidase
(HRP)-conjugated anti-human polyclonal antibody was used as a sec-
ondary antibody and 3′-diaminobenzidine as a chromogen. The section
was counterstained with hematoxylin.
2.7. Viral RNA Extraction and Viral Isolation
Viral RNA was extracted from 0.1 ml of serum or 0.2 ml of urine, sa-
liva and lacrimal ﬂuid samples as well as supernatants of tissues using a
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manufacturer's instructions. RNA was eluted in 60 μl of RNase-free
water, aliquoted, and stored at−80 °C until use.
For virus isolation, virus titers of the selected tissues (Threshold
cycle (Ct) values b 30) were determined by plaque forming assay on
BHK-21 cells. Brieﬂy, BHK-21 cells in 12-well plates were infected
with a 10-fold serially diluted suspension. The plates were incubated
at 37 °C for 1 h with gentle rocking every 15 min. The supernatant
was removed, and cells were overlaid with 1% low-melting-point aga-
rose (Promega) in DMEM containing 2% FBS. After further incubation
at 37 °C for 3–4 days, the cells were ﬁxed with 4% formaldehyde and
stained with 0.2% crystal violet to visualize the plaques.
2.8. ZIKV RNA Quantiﬁcation by qRT-PCR
The Xho I-linearized plasmid containing full-length genomic cDNA
clone of ZIKV strain GZ01/2016 was subjected to in vitro transcription
using RiboMAX Large Scale RNA Production System (Promega). The
RNA transcript was puriﬁed using PureLink RNAminikit (Life Technolo-
gy) according to the manufacturer's instructions and quantiﬁed using
spectrophotometry on Nanodrop®. The puriﬁed RNA was diluted 10-
fold serially using RNases-free water and was detected using quantita-
tive real-time reverse transcriptase PCR (qRT-PCR). Threshold cycle
(Ct) values for the known concentrations of the RNA were plotted
against the log of the number of genome equivalent copies. The resul-
tant standard curve was used to determine the number of genome
equivalents of ZIKV RNA in samples. The determination of the detection
limit was based on the lowest level atwhich viral RNAwas detected and
remained within the range of linearity of a standard curve. (Ct valuesb
38.5). qRT-PCR was performed using One Step PrimeScript™ RT-PCR
Kit (Takara, Japan) with the primers and probe (Table S1) as described
previously (Li et al., 2016). The 20 μl reaction mixtures were set up
with 2 μl of RNA. Cycling conditions were as follows: 42 °C for 5 min,
95 °C for 10 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 20 s.
2.9. Detection of ZIKV Strand Speciﬁc RNA by Quantitative PCR
For quantiﬁcation of ZIKV genomic RNA of both positive- and
negative-strands in speciﬁc organs with high viral RNA loads (Ct values
b30), the 5′-tagged forward (ZIKV-ASF-Tag) and reverse (ZIKV-ASR-
Tag) primers (Table S1) were used to obtain cDNA from the negative-
(-RNA) and positive-strand RNA (+RNA), respectively (Plaskon et al.,
2009). Brieﬂy, cDNA was synthesized with Superscript II (Invitrogen)
at 50 °C for 30min, and then heat inactivated at 95 °C for 15min. Quan-
titative PCR (qPCR) was then performed with the speciﬁc primers and
probe for strand speciﬁc RNA detection. The 20 μl reaction mixtures
were set up with 5 μl of cDNA. Cycling conditions were as follows:
95 °C for 10 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 20 s.
The copy numbers of viral RNAs were quantitated as above mentioned.
2.10. Antibody Response Assays
Serum IgM and IgG antibodies against ZIKV were detected by ELISA
using formaldehyde-inactivated ZIKV. Brieﬂy, 96-well microtiter plates
were coated overnight with 103 PFU of inactivated ZIKV. Diluted plasma
samples (1:50)were incubatedwith the coated antigen for 2 h, followed
by 1 h incubation of either HRP-conjugated goat-anti-monkey IgM or
IgG (Abcam, UK). After washing, TMB-substrate (Promega, USA) was
added to thewells and the plate was incubated for 10min at room tem-
perature in darkness. Then, 2.0 MH2SO4was added to stop the reaction,
and plates were measured at 450 nm using a microplate reader
(Beckman, USA). Endpoint titers were considered the highest dilution
that resulted in a value two-fold greater than the absorption of the con-
trol serum, with a cut-off value of 0.05.
Neutralizing antibody titers were determined by a constant virus-
serum dilution 50% plaque reduction neutralization test (PRNT50) aspreviously described. Brieﬂy, serial 2-fold dilutions of inactivated
serumweremixedwith equal volumes of ZIKV in DMEM supplemented
with 2% FBS. After incubation at 37 °C for 1 h, virus-antibody mixtures
were added to plates containing BHK-21 cells. The concentration of in-
fectious virus was determined using the plaque assay described above.
The endpoint neutralization titer was calculated according to themeth-
od of Reed and Muench.2.11. Biochemistry and Hematology Analysis
A panel of hematological parameters i.e. white blood cell count
(WBC), red blood cell count (RBC), hemoglobin (HGB), platelets (PLT),
lymphocytes (LYM), monocytes (MON) and neutrophils (NEUT) were
analyzed in peripheral blood using a Celltac E MEK-7222 hematology
analyzers (Nihon Kohden, Japan). Biochemical analysis, i.e. alanine
amino-transferase (ALT), aspartate aminotransferase (AST), total pro-
tein (TP), albumin (ALB), glucose GLU, urea (UREA) and creatinine
(CREA) was assessed using a 7100 automated biochemical analyzer
(Hitachi, Japan).2.12. Cellular Immune Response
Cellular immune responses were assessed in PBMC by the gamma
interferon (IFN-γ), interleukin 2 (IL-2) or IL-10 enzyme-linked immu-
nosorbent spot (ELISPOT) human set (Abcam, UK) according to the
manufacturer's protocol. Brieﬂy, PBMCs were thawed and washed
with Hanks balanced salt solution (HBSS). The cells were then centri-
fuged at room temperature at 2500 rpm for 15 min without braking,
followed by two washes with HBSS. Then, the cells were resuspended
in RPMI 1640 containing 10% FBS and diluted to a working concentra-
tion of 5 million cells per ml. For ELISPOT analysis, 0.5 or 0.1 million
cells per well were seeded with the appropriate antigen stimulation in
96-well tissue culture dishes coated with 5 mg/ml of IFN-γ, IL-2 or IL-
10 capture monoclonal antibody. Nonstimulated and PMA (Sigma)-
stimulated cells were used as negative and positive controls, respective-
ly. The cells were then cultured for 20 h at 37 °C and 5% CO2. Plates were
washed, and biotinylated anti-human IFN-γ, IL-2 or IL-10 antibody was
added to eachwell and incubated for 2 h at room temperature. Thereaf-
ter, the plates were washed and incubated for 1 h at room temperature
with streptavidin- horseradish peroxidase (streptavidin-HRP). Finally,
AEC substrate solution (Abcam, UK)was added and spots were counted
with an ELISPOT Analysis System (At-Spot-2100, China). Assay results
are expressed as the value obtained by the following: (number of
spots in experimental well-number of spots in medium control) / 106
cells.2.13. ZIKV Genome Sequencing and Detection of the SNP Sites
Viral RNAwas isolated using a PureLink RNAminikit (Life Technolo-
gy, USA) according to the manufacturer's instructions. The genome
cDNA was obtained by reverse transcription (RT) using SuperScript III
(Life Technology, USA). For determination of consensus sequence, PCR
products were directly sequenced by Sanger sequencing in both direc-
tions using virus-speciﬁc primers (Table S1). Sequence fragments
were assembled into a consensus sequence with DNASTAR software,
version 7.0.
High throughput sequencing was performed on an Illumina MiSeq
sequencingmachine. The genome sequences of the viruseswere assem-
bled bymapping the reads to the reference genomeof ZIKV strain GZ01/
2016. Genomicmapping and single nucleotide polymorphism(SNP) de-
tection were processed with CLC Genomic Workbench. The site with
substitution frequency above 5% was considered as a single nucleotide
variant (iSNV).
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3.1. ZIKV Causes Fever and Viremia in Rhesus Macaques
In the present study, to mimic the natural mosquito-biting route of
ZIKV,ﬁve adult rhesusmacaques agedﬁve years oldwere s.c. inoculated
with 105 PFU of ZIKV strain GZ01/2016. Fig. 1a outlines the timeline for
clinical manifestations, sample collection, and necropsies. Fig. S1 sum-
marizes the experimental results from each animal. Within 10 days
post-infection (p.i.), four out of ﬁve animals displayed fever (axillary
temperature N 38.9 °C) with peak temperature of 40.1 °C (Fig. 1b). The
forehead temperature also increased upon infection in all inoculated
monkeys (Fig. S2). Interestingly, ﬂuctuant fever was observed in two
animals between days 17 and 27 p.i. (Fig. 1b). No additional signs
(e.g., rash and hyperemia) or behavioral abnormalities (e.g., diarrhea,
inappetence, dehydration, depression, inactivity, self-injurious, or ste-
reotypical behavior) were observed throughout the experimental
period.
Blood chemistry analysis and complete blood cell counts were per-
formed at the indicated times. High levels of liver enzyme alanine ami-
notransferase (ALT) and aspartate aminotransferase (AST) were
observed (Fig. S3a). These enzymes increased signiﬁcantly at days 1
and 8 p.i., suggesting that liver dysfunction might be an early sign of in-
fection. In addition, a sharp increase in creatinine (CREA) level was de-
tected in two ZIKV-infected animals (Fig. S3a). Some minor changes
were observed in blood parameters in several animals, but the values
remained within normal variation ranges (Fig. S3b).
Viremia iswell documented as themarker forﬂaviviral replication in
vivo. Bloodwas sampled daily for 10 days p.i. and every 3–5 days there-
after (Fig. 1a). Plasma viremiawas detected by ZIKV-speciﬁc qRT-PCR in
all tested animals. All animals developed viremia, and themean viremia
duration was 6.6 days. Peak plasma viremia occurred between days 2
and 5 p.i., and ranged from 104.16 to 105.82 RNA copies/mL (Fig. 2a),
which is equivalent to those observed in patients (Lanciotti et al.,Fig. 1. Study design andbody temperature change in ZIKV-infected rhesusmonkeys. (a) Study d
of ZIKV strain GZ01/2016. Disease parameters were measured including body temperature,
monitored to evaluate viral kinetics in monkeys. Grey balls indicate detection time points. (b)
line indicates the temperature (38.9 °C) for fever determination.2008). By day 10 p.i., viremiawas undetectable in all animals; However,
low level of plasma viral RNA (104.57 RNA copies/mL) re-emerged in
two animals (R0082 and R3076) on days 17 and 27 p.i. (Fig. 2a).
Taken together, the currently circulating ZIKV strain can cause fever
and viremia in adult rhesus macaques, which partly recapitulates the
clinical manifestations of ZIKV infection in humans.3.2. ZIKV Viral RNA Excretion in Various Body Fluids
Viral shedding in body ﬂuids is critical for both disease diagnosis and
virus transmission, we then assayed the viral RNA kinetics in various
body ﬂuids. Remarkably, ZIKV RNA could be readily detected in urine
of all infected animals on day 1 p.i., and the levels of viral RNA peaked
on days 5 to 7 with 104.51 RNA copies/ml. The mean duration time
was 7.5 days. Prolonged viral RNA shedding was observed in two ani-
mals on days 14 and 17 p.i., and low levels of ZIKV RNA re-appeared
in urine after one month in two animals (Fig. 2b). In saliva, viral RNA
could be detected on day 3 p.i. and afterwards, and peaked at 3–
9 days p.i. Prolonged shedding of viral RNA in saliva was also observed
in two animals (Fig. 2c). These observations are in agreementwith clin-
ical results that ZIKVRNAwas detected in urine and saliva (Barzon et al.,
2016; Gourinat et al., 2015; Roze et al., 2016).
Unexpectedly, robust viral RNA shedding was detected in lacrimal
ﬂuid in four of the ﬁve animals from days 1 to 10 p.i., and peaked at
2–5 days p.i. Especially, viral RNA was detected in two macaques on
day 17 p.i. (Fig. 2d). Ocular complications have been recently described
in ZIKV patients (de Paula Freitas et al., 2016; Ventura et al., 2016a),
here demonstrated the excretion of ZIKV RNAs in lacrimal ﬂuid in
ZIKV-infected animals. Additionally, ZIKV RNAwas detected in the cere-
brospinal ﬂuid (CSF) on day 5 p.i. (Fig. S1). Overall, ZIKV RNA shedding
was detected in multiple body ﬂuids, and it is notable that viral RNA
levels were different among distinct body ﬂuids, in the order of
blood N lacrimal ﬂuid ≥ saliva N urine.esign and experimental parameters. Five rhesusmonkeyswere s.c. inoculatedwith 105 PFU
blood cell count, and blood chemistry. Viral loads in blood and major body ﬂuids were
Change in axillary temperature of rhesus monkeys after s.c. infection with ZIKV. Dotted
Fig. 2. Excretion of viral RNAs in ZIKV-infected rhesus monkeys. (a) Blood. (b) Urine. (c)
Saliva. (d) Lacrimal ﬂuid. Dotted lines indicate the limit of detection.
Fig. 3.Detection of viral RNA in tissues of ZIKV-infected rhesusmonkeys. Viral RNA,+RNA
(positive-strand viral RNA) and−RNA (negative-strand viral RNA) were determined in
tissues of ZIKV-challenged rhesus monkeys on day 5 (a) and day 10 (b) p.i. The
corresponding primers and probeswere listed in Table S1. ND, not detectable. #, not done.
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To verify the in vivo target organs and the pathological changes
caused by ZIKV infection, we euthanized two animals and performed
necropsies at days 5 and 10 p.i., respectively. On day 5 p.i., ZIKV RNA
was detected in both central nervous system (CNS; including cerebrum,
cerebellum, brain stem, and spinal cord), and visceral organs (including
liver, kidney, spleen, parotid glands, large intestine, small intestine,
cecum, bladder, testes, lymph node, heart, and stomach). The highest
level of viral RNA was detected in large intestine, small intestine,
cecum, spleen and parotid glands (Fig. 3a). The intestines have also
been documented as potential target organs of DENV infection in mice
(Schoggins et al., 2012). Interestingly, on day 10 p.i., viral RNA was
cleared in most tissues except for spinal cord, spleen, lymph node,
liver, kidney, pancreas, and stomach (Fig. 3b). Although samples were
collected from two animals, viral RNAs in spleen and lymph nodes
were higher than that on day 10 p.i. compared with that on day 5 p.i.,
suggesting potential active viral replication in these tissues at later
stage of ZIKV infection. Signiﬁcantly, negative-strand ZIKV RNAwas de-
tected in spleen, parotid glands, large intestine, small intestine, and
cecum on day 5 p.i.,(Fig. 3a) and on day 10 p.i. spleen and lymph
nodes still tested positive for negative-strand ZIKV RNA (Fig. 3b). The
level of negative-stand RNA in each tested organ was much lower
than that of positive-strand RNA as expected (Table S2). Infectious
ZIKV was also directly recovered from the above-mentioned target or-
ganswithhigh viral load. Together, all these results demonstrated active
ZIKV replication in these organs.
Immunohistochemistry using a pan-ﬂavivirus mouse monoclonal
antibody 2A10G6 (Dai et al., 2016) revealed that ZIKV-speciﬁc antigenswere present in multiple CNS and peripheral organs during the acute
phase of infection (Fig. 4a), which was in agreement with the results
of viral RNA detection (Fig. 3). Histopathological examination showed
substantial pathological changes in cerebrum, cerebellum, brain stem,
liver, and spleen on day 5 p.i., characterized by vascular cufﬁng in cere-
brum and brain stem, inﬂammatory cell inﬁltration in liver, and hemor-
rhage in spleen (Fig. 4b). Liver damage has been previously described in
ZIKV patients (Macnamara, 1954), and is potentially relevant to the el-
evated levels of AST and ALT observed in our study (Fig. S3a). Collective-
ly, these above observations suggested that (i) ZIKV established
systematic infections involving both CNS and visceral organs at the
early stage; (ii) intestinal tracts, spleen, and parotid glands are the
major target organs of ZIKV; (iii) lymphnodes and spleen support active
ZIKV replicationwhenviremia and clinical symptomshave disappeared.
Additionally, routine viral genome sequencing of samples from the
selected organs failed to identify any adaptive mutation in all tested
samples. High-throughput sequencing was then performed by using
an Illumina MiSeq sequencing machine. Genomic alignment revealed
a panel of intrahost single nucleotide variants (iSNV) distributed within
the full genome in individual samples (Fig. 5 and Table S3). The highest
diversity was observed in the lymph nodes on day 10 p.i. Three consen-
sus sequence changes were detected in the spleen, cecum and lymph
nodes (Fig. 5), two of which were nonsynonymous iSNVs (M73 V in
prM and A227 V in E). The biological importance of these adaptive mu-
tations in viral tropism and dissemination deserve further investigation.
3.4. ZIKV Induces Robust Humoral and Cellular Response
Finally, to make sure whether the animal model described here
could be used for vaccine efﬁcacy tests, we further examined the
ZIKV-speciﬁc humoral and cellular immune responses in all ZIKV-inoc-
ulated animals. As shown in Fig. 6a, ZIKV-speciﬁc IgM antibodies ap-
peared on day 1 p.i., and rapidly increased on day 10 p.i. in all animals.
The IgG kinetics was slightly delayed compared with IgM, and peaked
on day 14 p.i. Importantly, all of the inoculated monkeys developed
moderate level of neutralizing antibodies against ZIKV on day 22 p.i.
(Fig. 6b).
Additionally, PBMC isolated from the infected animals were stimu-
lated with ZIKV antigen and subjected to ELISPOT assay. Rapid increase
in the production of IFN-γ, IL-2, and IL-10 were detected in all monkeys
Fig. 4. Immunohistochemistry and histopathological changes of tissues of inoculated rhesus monkeys. (a) Immunohistochemistry of tissues of inoculated rhesus monkey on day 5 p.i.
Samples were stained with the pan-ﬂavivirus mouse monoclonal antibody 2A10G6. Brown colored staining suggests ZIKV infection. (b) Histopathological changes of tissues of
inoculated rhesus monkeys on days 5 and 10 p.i. Arrows denote vascular cufﬁng (V), mononuclear inﬂammatory cell inﬁltration (M), inﬂammatory cell inﬁltration (I), and
hemorrhage (H).
175X.-F. Li et al. / EBioMedicine 12 (2016) 170–177except one (R3016) on day 14 p.i. (Fig. S4). Collectively, these observa-
tions demonstrate that the subcutaneous inoculation of ZIKV induced
humoral and cellular immune responses in rhesus monkeys, which
paves the road to a ZIKV vaccine.
4. Discussion
Themechanismof ZIKVpathogenesis remains largely unclear. This is
partly due to the lack of a robust animal model that recapitulates theFig. 5. Genetic diversity of ZIKV in various tissues from the rhesus monkey. Conclinical manifestations and disease kinetics as seen in ZIKV patients.
Our results showed that rhesus macaques could be infected by the con-
temporary ZIKV strain that is circulating in south Americas. This non-
human primate model described here partly recapitulates some clinical
features and viral kinetics in ZIKV-infected patients, and therefore may
serve as a model to study ZIKV disease and pathogenesis. Very recently,
a rhesus macaque model of ZIKV infection was reported with a clinical
strain isolated in French Polynesian in 2013 (Dudley et al., 2016). The
2013 ZIKV strain caused viremia and viral RNA shedding in urine andsensus changes found in tested tissues were connected with dotted lines.
Fig. 6.Humoral immune responses in ZIKV-infected rhesus monkeys. (a) Serum IgM and IgG antibodies against ZIKV were detected by ELISA using formaldehyde-inactivated ZIKV as an
antigen source. The dotted lines represent the limits of detection of the ELISA assigned values of 100. (b) Neutralizing antibody titer of rhesusmonkeys after s.c. challengewith ZIKV. Serial
dilutions of inactivated serumwere mixedwith ZIKV. The concentration of infectious virus was determined using the plaque assay on BHK-21 cells. The endpoint neutralization titer was
calculated according to the method of Reed and Muench. The dotted lines represent the limits of detection of the PRNT50 assigned values of 10.
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cially, inappetence was seen in most ZIKV-infected animals (Dudley et
al., 2016), and no other abnormal clinical sighs were noted in their
study. In our study, four of ﬁve rhesus macaques developed fever
upon ZIKV infection, that is directly associated with disease. The chal-
lenge dose used in Dudley's experiments was 100-fold lower than that
in our study, whichmay account for the difference in clinical symptoms.
The viral shedding features in various body ﬂuids in ZIKV-infected
macaques correlated with the clinical ﬁndings from patients. The pres-
ence of high loads of viral RNA in these body ﬂuids supports that besides
blood, urine and saliva are now used for clinical diagnosis of ZIKV. Espe-
cially, our results demonstrate that viral RNA was abundant in lacrimal
ﬂuids in ZIKV-infected adult macaques, supporting the use of tears or
lacrimal ﬂuids for clinical diagnosis. ZIKV-associated damages have
been documented in babies with microcephaly (de Paula Freitas et al.,
2016; Ventura et al., 2016a; Ventura et al., 2016b), and conjunctivitis
is also a common symptom in adult ZIKV patients (Dasgupta et al.,
2016; Deng et al., 2016; Duffy et al., 2009). Whether the level of viral
RNA in body ﬂuids associated with disease severity remains unknown.
The in vivo replication kinetics of ZIKV in natural human infections
remains elusive. The neurotropic nature of ZIKV has been evidenced
by mouse experiments (Cugola et al., 2016) and clinical investigations
(Carteaux et al., 2016). Our necropsy data from two animals demon-
strate that the contemporary ZIKV strain can invade and replicate with-
in the CNS system of macaques following s.c. inoculation, despite no
neurological signs developed. However, the viral loads in CNS tissues
are quite lower than other major target organs. In our experiments,
few viral RNA or proteins was detected in the genital organs except
bladder and testis on day 5 p.i. (Fig. 3), and no obvious pathological
changes were seen in these organs. We are not able to collected
semen samples due to technical reasons. High levels of positive- and
negative-strand ZIKV RNAs were detectable in potential target organs
at different stages of infection (day 5 or day 10 p.i.), and infectious
ZIKV can be directly recovered from selected organs with high viral
load. Unexpectedly, our results suggest that the parotid gland, besides
intestinal tracts and spleen, represents potential major target tissues
of ZIKV. The parotid gland serves as the viral replication site and exit
portal for the highly neurotropic rabies virus into saliva (Boonsriroj etal., 2016). Although the biological importance of ZIKV replication in pa-
rotid gland remains unknown, a probable connection to the persistent
excretion of viral RNA in saliva is highly suspected. Since our results
are only from two animals dissected at different time, the in vivo kinetic
of ZIKV replication deserves extensive investigation in the future.
In addition, the non-human primate model described here could be
used to evaluate ZIKV vaccine or antiviral candidates. The reduction of
body temperature increase, viremia, and excretion of viral RNA in vari-
ous bodyﬂuids upon ZIKV infection could serve as endpoints for protec-
tion in vaccine or antiviral efﬁcacy test. A large panel of ZIKV vaccine
candidates is being developed in an expeditedmanner by using existing
ﬂavivirus vaccine platforms, e.g., chimeric live attenuated strains, killed
virons, recombinant subunit viral proteins, subviral particles, or DNA
plasmids, and clinical trials are highly expected in the near future
(Weaver et al., 2016). The non-human primate model described here
could serve as a gatekeeper for advancing vaccine candidates into
clinics. Any candidate ZIKV vaccine is supposed to induce protective im-
mune response and confer protection against contemporary ZIKV strain
challenge in non-human primate model.
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